Weill Cornell Clinical Study Notes Cesium-131 Brachytherapy Can Provide a Viable Alternative to Whole Brain Radiotherapy With Excellent Response Rates and Minimal Toxicity

RICHLAND, WA--December 14, 2015) - IsoRay Inc. (ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the recent publication of the peer-reviewed results of a study entitled: "Neurocognitive function and quality of life in patients with newly diagnosed metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial."

VirtualScopics, Inc. Reports 2015 Third Quarter Revenues Increase 18% From Prior Year Period And Company Achieves Positive Adjusted EBITDA

ROCHESTER, N.Y., Oct. 29, 2015 -- VirtualScopics, Inc. (VSCP), a leading provider of clinical trial imaging solutions, today reported financial results for the third quarter and nine months ended September 30, 2015.

Revenues for the third quarter of 2015 increased 18% to $3,224,407 compared to $2,741,241 for the third quarter of 2014. The company reported positive Adjusted EBITDA in the third quarter of 2015 of $132,101 as compared to negative Adjusted EBITDA of $842,772 in the third quarter of 2014. VirtualScopics reported a net loss for the third quarter of 2015 of $24,779, or $0.02 loss per share, representing a 97% improvement from a net loss of $955,523, or $0.33 loss per share, reported in the third quarter of 2014.

Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders

Combined Product Portfolio to Provide Clinicians With a Broad Range of Endovascular AAA Devices
Will Expand U.S. and European Sales Organizations to Enhance Growth and Provide Excellent Clinical Support
Endologix to Host Conference Call Today at 5:00 p.m. ET

IRVINE, Calif., and SANTA ROSA, Calif., Oct. 26, 2015  -- Endologix, Inc. (ELGX) and TriVascular Technologies, Inc. (TRIV) announced today that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. The transaction is valued at $9.10 per TriVascular share, or a total of approximately $211 million, based on Endologix's closing stock price of $13.81 per share on October 23, 2015.

Spectranetics Achieves Third Quarter 2015 Revenue of $61.7 Million

COLORADO SPRINGS, Colo., Oct. 22, 2015 -- The Spectranetics Corporation (SPNC) today reported financial results for the three and nine months ended September 30, 2015. Highlights of the quarter, all compared with the three months ended September 30, 2014 include:

• Revenue of $61.7 million increased 5% (7% constant currency¹)
• Vascular Intervention revenue of $40.4 million increased 10% (12% constant currency)
• Lead Management revenue of $18.0 million increased 2% (5% constant currency)

"We are pleased with our third quarter results, marked by solid performance within our Vascular Intervention, Lead Management and International businesses. We believe that our team, portfolio, product pipeline and clinical data position us to capitalize on the compelling growth opportunities ahead," said Scott Drake, President and Chief Executive Officer.